Unknown

Dataset Information

0

Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid.

ABSTRACT:

SUBMITTER: Said JT 

PROVIDER: S-EPMC9946809 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid.

Said Jordan T JT   Talia Jordan J   Wei Erin E   Mostaghimi Arash A   Semenov Yevgeniy Y   Giobbie-Hurder Anita A   Chen Steven T ST   LeBoeuf Nicole R NR  

Journal of the American Academy of Dermatology 20220630 3

Similar Datasets

Unknown Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: Successful Treatment with Dupilumab while Maintaining Immunotherapy.
| S-EPMC12503597 | biostudies-literature
Unknown Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma.
| S-EPMC12507624 | biostudies-literature
Unknown Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review.
| S-EPMC9596715 | biostudies-literature
Unknown Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
| S-EPMC10947518 | biostudies-literature
Unknown Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
| S-EPMC9524245 | biostudies-literature
Unknown Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.
| S-EPMC12404300 | biostudies-literature
Unknown Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
| S-EPMC9008562 | biostudies-literature
Unknown Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.
| S-EPMC10191203 | biostudies-literature
Unknown Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database.
| S-EPMC12819333 | biostudies-literature
Unknown Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.
| S-EPMC9188788 | biostudies-literature